64
Participants
Start Date
November 6, 2014
Primary Completion Date
October 13, 2016
Study Completion Date
October 13, 2016
Lebrikizumab
Lebrikizumab will be administered by SC injection on Day 1, Day 8, Week 4, and Week 8.
Placebo
Lebrikizumab matching placebo will be administered by SC injection on Day 1, Day 8, Week 4, and Week 8.
Inhaled corticposteroids (ICS)
Participants will continue their ICS controller therapy, as they are receiving prior to screening, throughout the study. Protocol does not specify any particular ICS.
Second Asthma Controller Medication
Participants will continue their asthma controller therapy, as they are receiving prior to screening, throughout the study.
Connolly Hospital, Dublin
University of Pittsburgh Medical Center Health System, Pittsburgh
Pen Memory Center, Philadelphia
Temple University Hospital ; Lung Center, Philadelphia
Duke University Medical Center, Durham
Groupe Hospitalier Sud - Hôpital Haut Lévêque, Pessac
Hôpital Arnaud de Villeneuve, Montpellier
University of Iowa Hospitals & Clinics; Internal Medicine, Iowa City
Northwestern University, Chicago
Washington University; Pediatrics, St Louis
Baylor College of Medicine, Houston
LAC-USC Medical Center, Los Angeles
University of California Davis Health System; Division of Pulmonary and Critical Care Medicine, Sacramento
University of Arizona, Tucson
Yale School of Medicine, New Haven
University of Miami School of Medicine - Sylvester at Deerfield, Deerfield Beach
Brigham and Women's Hospital; Pulmonary Division, Boston
Wake Forest University Baptist Medical Center; Gastroenterology & Digestive Health, Winston-Salem
UTMB Pathology Clinical Services, Galveston
University of Calgary, Calgary
University of Alberta Hospital-SCC/WCM, Edmonton
VGH Research Pavilion, Vancouver
McMaster University Health Sciences Center, Hamilton
Skånes Universitetssjukhus, Lund, Lund
Queen's University Belfast; NICRN Respiratory Research Office, Belfast
Glenfield Hospital, Leicester
St Mary's Hospital, London
The Medicines Evaluation Unit, Manchester
Hoffmann-La Roche
INDUSTRY